BridgeBio's lean focus on genetic drivers scores 2nd drug approval in 3 months

The newest oral drug will cost about $21,500 per month to tackle one of the most aggressive forms of cancer. But the company also expects mid-stage clinical results later this year for the same drug as a treatment for a form of dwarfism.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news

Related Links:

Condition:   Oral Squamous Cell Carcinoma Intervention:   Diagnostic Test: MMP-1 Enzyme Linked Immunosorbent assay (ELISA) Sponsor:   S&T  Biomed Co., Ltd. Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The EuroQol 5-dimension 5-level (EQ-5D-5L) instrument is among the most used preference-based quality of life (QOL) measures for cost –utility analysis. Each dimension is evaluated on five levels. The aim of this study was to clarify whether the EQ-5D-5L, which consists of only five items, correlates with profile-based QOL measures in Japanese oral cancer patients during the perioperative period. One hundred participants with or al cancer undergoing radical therapy completed QOL assessments before treatment, at treatment completion, and 1 and 3 months after treatment using the EQ-5D-5L and Functional Assessment of Ca...
Source: International Journal of Oral and Maxillofacial Surgery - Category: ENT & OMF Authors: Tags: Research Paper Source Type: research
ConclusionOur study suggests that NTT plays a key role in HCC progression via MYB-regulated target genes and may serve as a novel therapeutic target.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and cataly...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Conclusions: The increased Ki-67 expression of oral cancer cells in response to 20% DPMSC-CM indicates the potential for cancer progression. Further research is needed to identify their effects on other carcinogenic properties, including apoptosis, stemness, migration, invasion, adhesion, and therapeutic resistance.
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
We report here a role for cathepsin S in PAR2-dependent cancer pain. We report that cathepsin S was more active in human oral SCC than matched normal tissue, and in an orthotopic xenograft tongue cancer model than normal tongue. The multiplex immunolocalization of cathepsin S in human oral cancers suggests that carcinoma and macrophages generate cathepsin S in the oral cancer microenvironment. After cheek or paw injection, cathepsin S evoked nociception in wild-type mice but not in mice lacking PAR2 in Nav1.8-positive neurons (Par2Nav1.8), nor in mice treated with LY3000328 or an endogenous cathepsin S inhibitor (cystatin ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
To investigate the association of genic region polymorphisms of FAS and FASL in Indian oral cancer subjects.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Tags: Original Article Source Type: research
ConclusionsA robust population PK model was built and qualified for entrectinib and M5, describing linear PK for both entities. This model was used to support the ROZLYTREK® new drug application.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
In this study, 600 oral photograph images were collected retrospectively and grouped into 300 images of OPMDs and 300 images of normal oral mucosa. CNN-based classification models were created using DenseNet-121 and ResNet-50. The detection models were created using Faster R-CNN and YOLOv4.
Source: International Journal of Oral and Maxillofacial Surgery - Category: ENT & OMF Authors: Tags: Research Paper Source Type: research
More News: American Health | Cancer | Cancer & Oncology | Genetics | Health Management | Oral Cancer